Overview Esperion is a commercial stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. We have developed and are commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease, or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. Through commercial execution, international partnerships and collab...
Q2 FY2026 — expected 2026-08-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-10 | 2025-12-31 | 0001628280-26-016522 | EDGAR | 109K words |
| 2025-03-07 | 2024-12-31 | 0001628280-25-011154 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0001628280-24-007066 | EDGAR | — |
| 2023-02-21 | 2022-12-31 | 0001628280-23-004167 | EDGAR | — |
| 2022-02-22 | 2021-12-31 | 0001628280-22-003263 | EDGAR | — |
| 2021-02-23 | 2020-12-31 | 0001628280-21-002865 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001104659-20-026203 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001047469-19-000791 | EDGAR | — |
| 2018-02-20 | 2017-12-31 | 0001047469-18-000899 | EDGAR | — |
| 2017-02-22 | 2016-12-31 | 0001047469-17-000831 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001628280-25-050165 | EDGAR | 34K words |
| 2025-08-13 | 2025-06-30 | 0001628280-25-040139 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001628280-25-023498 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001628280-24-046307 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001628280-24-036762 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001628280-24-020862 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001628280-23-037195 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0001628280-23-026358 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001628280-23-016646 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0001628280-22-027479 | EDGAR | — |
| 2022-08-02 | 2022-06-30 | 0001628280-22-020111 | EDGAR | — |
| 2022-05-03 | 2022-03-31 | 0001628280-22-011885 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001628280-26-023196 | EDGAR | 77K words |
| 2026-03-10 | 0001628280-26-016230 | EDGAR | — |
| 2026-03-03 | 0001628280-26-013552 | EDGAR | — |
| 2026-01-12 | 0001628280-26-001764 | EDGAR | — |
| 2025-11-06 | 0001628280-25-049866 | EDGAR | — |
| 2025-11-04 | 0001628280-25-048557 | EDGAR | — |
| 2025-10-08 | 0001104659-25-097992 | EDGAR | — |
| 2025-10-07 | 0001104659-25-097506 | EDGAR | — |
| 2025-08-05 | 0001628280-25-037601 | EDGAR | — |
| 2025-07-01 | 0001628280-25-033612 | EDGAR | — |
260 total filings indexed. 228 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001434868 |
| Ticker | ESPR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.esperion.com |
| Listed | 2013-06-26 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report